Behavioral characterization of ayahuasca treatment on Wistar rats in the open field test
Keywords:
Ayahuasca; Rat model; Open field test; Behavioral testsAbstract
Ayahuasca (AYA) is a psychedelic beverage with therapeutic potential for many mood and anxiety disorders. Although there are some preclinical studies, no published reports have tested the behavioral effects of AYA gavage in animal models. This investigation aimed to characterize the behavior of Wistar rats after acute ingestion of AYA for 40 min in the open field test (OFT). The sample consisted of three experimental groups treated with different dosages of AYA (125, 250, or 500 mg kg-1) and a control group. Each group consisted of 10 participants. After gavage, the number of crossings of the OFT grid lines, latency to enter the central area of the device, grooming frequency, and time spent in the central perimeter of the device were immediately evaluated. Analyses were based on one-way ANOVA and a linear-regression mixture model for longitudinal data. AYA intake did not interfere with habituation. The 500 mg kg-1 group showed a decrease in the time spent in the center of the device and in the number of crossings compared to the control group in the last 10 min. These results suggest that gavage with AYA did not interfere with the results, and the behavioral effects were perceived only between 30 and 40 min after gavage. Taken together, the results indicate that three aspects should be considered in OFT studies of AYA acute effects: the moment when the observation starts, the observation period, and the AYA dosage.
Downloads
References
Bacqué-Cazenave J, Bharatiya R, Barrière G, Delbecque JP, Bouguiyoud N, Di Giovanni G, De Deurwaerdère P, et al. Serotonin in animal cognition and behavior. Int J Mol Sci. 2020;21(5):1649.
Brito-da-Costa AM, Dias-da-Silva D, Gomes, NGM, Dinis-Oliveira RJ, Madureira-Carvalho Á. Toxicokinetics and toxicodynamics of ayahuasca alkaloids n,n-dimethyltryptamine (dmt), harmine, harmaline and tetrahydroharmine: Clinical and forensic impact. Pharmaceuticals. 2020;13(11):334.
Carbonaro TM, Gatch MB. Neuropharmacology of N, N-dimethyltryptamine. Brain Res Bull. 2016;126(1):74-88.
Castro-Neto EF, Da Cunha RH, Da Silveira DX, Yonamine M, Gouveia TLF, Cavalheiro EA, et al. Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World J Biol Chem. 2013;4(4):141-7.
Frecska E, Bokor P, Winkelman M. The therapeutic potentials of ayahuasca: Possible effects against various diseases of civilization. Front Pharmacol. 2016;7:35.
Gałecki P, Talarowska M. Inflammatory theory of depression. Psychiatr Polska. 2018;52(3):437-47.
Gould TD, Dao DT, Kovacsics CE. The Open Field Test. In Gould TD (Ed.). Neuromethods, Baltimore: Human Press. 2009; 1-20.
Kjellgren A, Eriksson A, Norlander T. Experiences of encounters with ayahuasca- “the vine of the soul”. J Psychoact Drugs. 2009;41(4):309-315.
Labate BC, Feeney K. Ayahuasca and the process of regulation in Brazil and internationally: Implications and challenges. Int J Drug Policy. 2012;23(2):154-161.
Lima LM, Ferreira SM, Avila AAL, Perazzo FF, Schneedorf JM, Hinsberger A, et al. Ayahuasca central nervous system effects: behavioral study. Phytotherapie. 2007;5(5):254.
McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther. 2004;102(2):111-129.
McKenna DJ, Towers GHN, Abbott FS. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca. J Ethnopharmacol. 1984;10(2):195-223.
Nunes AA, Dos Santos RG, Osório FL, Sanches RF, Crippa JAS, Hallak JE. Effects of ayahuasca and its alkaloids on drug dependence: a systematic literature review of quantitative studies in animals and humans. J Psychoact Drugs . 2016;48(3):195-205.
Oliveira-Lima AJ, Santos R, Hollais AW, Gerardi-Junior CA, Baldaia MA, Wuo-Silva R, et al. Effects of ayahuasca on the development of ethanol-induced behavioral sensitization and on a post-sensitization treatment in mice. Physiol Behav. 2015;142:28-36.
Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663.
Pekár S, Brabec. Generalized estimating equations: A pragmatic and flexible approach to the marginal GLM modelling of correlated data in the behavioral sciences. Ethology. 2018;124(2):86-93.
Pic-Taylor A, da Motta LG, de Morais JA, Junior WM, Santos A de FA, Campos LA, et al. Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotriaviridis) in female Wistar rat. Behav Processes. 2015;118:102-110.
Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003;463(1-3):3-33.
Ruffell S, Netzband N, Bird C, Young AH, Juruena MF. The pharmacological interaction of compounds in ayahuasca: a systematic review. Braz J Psychiatry. 2020;42(6):646-656.
Dos Santos RG, Hallak JE. Effects of the natural β-carboline alkaloid harmine, a main constituent of ayahuasca, in memory and in the hippocampus: A systematic literature review of preclinical studies. J Psychoact Drugs . 2017;49(1):1-10.
Dos Santos RG, Osório FL, Crippa JAS, Hallak JEC. Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. Braz J Psychiatry . 2016;38(1):65-72.
Wu H, Denna TH, Storkersen JN, Gerriets VA. Beyond a neurotransmitter: The role of serotonin in inflammation and immunity. Pharmacol Res. 2019;140:100-114.
Xavier J, Farias CP, Soares MSP, Silveira GO, Spanevelo RM, Yonamine M, et al. Ayahuasca prevents oxidative stress in a rat model of depression elicited by unpredictable chronic mild stress. Arch Clin Psychiatr. 2021;48(2):90-98.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
